Zuoshang Xu and Paul Thompson Labs receive new NIH RO1 award
Date Posted: Monday, May 10, 2021
Zuoshang Xu and Paul Thompson receive a new NIH RO1 award to study protein citrullination and its role in ALS, a fatal neurodegenerative disease. ALS is also known as Lou Gehrig's disease. It causes paralysis and death and is currently incurable. The Xu and Thompson labs aim to understand the changes in protein citrullination during the ALS progression and investigate the effects of these changes. This research may pave the way for new biomarkers and/or therapeutic avenues for ALS.
For more about the Zuoshang Xu Lab, please visit www.umassmed.edu/zxulab
Fore more about the Thompson Lab, please visit www.umassmed.edu/thompson